The Vascular Endothelial Growth Factor-A121/Vascular Endothelial Growth Factor-A165 Ratio as a Predictor of the Therapeutic Response to Immune Checkpoint Inhibitors in Gastric Cancer
The serum VEGF-A121/165 ratio may represent a new, easily measured biomarker for predicting the therapeutic response to ICIs.
Authors
- Yuto Hozaka (ORCID: https://orcid.org/0000-0003-0655-4488)
- Munekazu Yamakuchi (ORCID: https://orcid.org/0000-0003-2181-7194)
- Chieko Fujisaki
- Takaaki Arigami (ORCID: https://orcid.org/0000-0001-8650-8937)
- Kazunori Takenouchi (ORCID: https://orcid.org/0000-0003-1946-457X)
- Drew N. Maywar (ORCID: https://orcid.org/0000-0002-2674-0520)
- Yoko Oyama
- Teruto Hashiguchi (ORCID: https://orcid.org/0000-0003-4820-8268)
- Masashi Okawa (ORCID: https://orcid.org/0000-0001-7618-2240)
- Sadayuki Higashi
- Yoshiaki Kita
- Daisuke Matsushita (ORCID: https://orcid.org/0000-0002-6765-9366)
- Kiyonori Tanoue (ORCID: https://orcid.org/0000-0002-9128-2298)
- Chieri Nakayama
- Takao Ohtsuka (ORCID: https://orcid.org/0000-0002-2946-1092)
- Shingo Yamada (ORCID: https://orcid.org/0000-0001-9488-668X)
- Yuki Hamada (ORCID: https://orcid.org/0000-0002-9835-7571)
Institutions
- Kagoshima University (JP)
- Rochester Institute of Technology (US)
- Shino-Test Corporation
Publication Details
- Journal
- Cancers
- Published
- 2024-11-26
- DOI
- https://doi.org/10.3390/cancers16233958
- Citations
- 3
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Japan Society for the Promotion of Science